Biosimilar Newsletter Archive
-
01.26.23 -- Make The Service Agreement Work For You And Your CDMO
1/26/2023
01/26/23 Biosimilar Development Newsletter
-
01.20.23 -- De-Risking Combination Product Development For Biosimilars
1/20/2023
01/20/23 Biosimilar Development Newsletter
-
01.19.23 -- 4 Key Takeaways For Combination Products As We Move Into 2023
1/19/2023
01/19/23 Biosimilar Development Newsletter
-
01.12.23 -- FDA Accepts Stelara Biosimilar BLA For Review
1/12/2023
01/12/23 Biosimilar Development Newsletter
-
01.05.23 -- Where Do We Stand On Adopting Continuous Manufacturing For Biologics?
1/5/2023
01/05/23 Biosimilar Development Newsletter
-
12.22.22 -- FDA Accepts Biogen BLA For Biosimilar Actemra
12/22/2022
12/22/22 Biosimilar Development Newsletter
-
12.15.22 -- ACMA Develops Board-Certified Biologics & Biosimilars Specialist Certification
12/15/2022
12/15/22 Biosimilar Development Newsletter
-
12.12.22 -- Don't Miss 6 Key Topics That Changed Biopharma Testing In 2022
12/12/2022
12/12/22 Biosimilar Development Newsletter
-
12.08.22 -- Biocon Completes Acquisition Of Viatris Biosimilar Business
12/8/2022
12/08/22 Biosimilar Development Newsletter
-
12.07.22 -- Top 2022 Articles On Process Development
12/7/2022
12/07/22 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more